Kamada Ltd. KMDA
Nov 5, 2026, 10:52 AM EST
- YTD
- -2.55%
- 1 year
- -0.43%
- Market cap
- 397.05M
- Revenue (ttm)
- 154.57M
- Profit margin
- 9.75%
- EPS (ttm)
- 0.38
- Shares out
- 57.49M
- P/E ratio
- 18.11
- Forward P/E
- 19.52
- Dividend yield
- 1.73%
- YTD return
- -2.55%
- 1-year return
- -0.43%
- Volume
- 123.11K
- Avg volume
- 132.16K
- Open
- 7.01
- Previous close
- 7.42
- Day's range
- 6.77 – 7.12
- 52-week range
- 6.55 – 9.35
- Beta
- 0.20
- Price target
- 14.67 (+113.2%)
2Y +0.93 (+15.53%)
Key statistics
- Enterprise value
- 276.22M
- PEG ratio
- 0.00
- Price / sales
- 2.33
- Price / book
- 1.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.40%
- Free cash flow
- -7.77M
- Total cash
- 56.55M
- Total debt
- 8.56M
- Return on equity
- 7.04%
- Short % of float
- 0.09%
- 50-day average
- 5.77
- 200-day average
- 5.52
Analyst view
- Target (low)
- 11.00
- Target (mean)
- 14.67
- Target (high)
- 20.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.07 | 0.07 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.06 | 0.08 | +0.02 | +33.33% |
| May 8, 2024 | Mar 1, 2024 | 0.06 | 0.04 | -0.02 | -33.33% |
| Mar 6, 2024 | Dec 1, 2023 | 0.05 | 0.09 | +0.04 | +80.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.03 | 0.06 | +0.03 | +100.00% |
| Aug 16, 2023 | Jun 1, 2023 | 0.02 | 0.04 | +0.02 | +100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 3, 2024 | Stifel | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- kamada.com
News
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026 
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 
Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products 
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel 
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth 
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth 
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand 
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference 
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders 
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Your note
Sign in to keep a note on KMDA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Phoenix Holdings Ltd. | 3.19% | 1,832,952 | 11.09M | Sep 29, 2024 |
| Vanguard Group Inc | 2.41% | 1,384,430 | 8.38M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.49% | 856,106 | 5.18M | Sep 29, 2024 |
| Y.D. More Investments Ltd | 1.23% | 709,551 | 4.29M | Sep 29, 2024 |
| Wells Fargo & Company | 1.10% | 629,884 | 3.81M | Sep 29, 2024 |
| Millennium Management Llc | 0.62% | 354,776 | 2.15M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 1.13% | 650,238 | 3.93M | Jul 30, 2024 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 0.54% | 308,828 | 1.87M | Sep 29, 2024 |
| DFA Continental Small Company Series | 0.35% | 203,071 | 1.23M | Jul 30, 2024 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 0.26% | 146,585 | 886.84K | Jul 30, 2024 |
| DFA International Core Equity Portfolio | 0.14% | 78,512 | 475.00K | Jul 30, 2024 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 0.13% | 73,700 | 445.88K | Aug 30, 2024 |